Premium
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL
Author(s) -
Jaeger U.,
Tam C.,
Borchmann P.,
McGuirk J.,
Holte H.,
Waller E.,
Jaglowski S.,
Andreadis C.,
Foley S.R.,
Fleury I.,
Westin J.,
Teshima T.,
Mielke S.,
Salles G.,
Ho P.J.,
Izutsu K.,
Schuster S.,
Bachanova V.,
Maziarz R.,
Van Besien K.,
Kersten M.J.,
WagnerJohnston N.,
Kato K.,
Corradini P.,
Tiwari R.,
Forcina A.,
Pacaud L.,
Bishop M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.189_2631
Subject(s) - hypogammaglobulinemia , medicine , refractory (planetary science) , rituximab , gastroenterology , immunology , antibody , lymphoma , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom